Shares of global vaccine makers were muted on Tuesday as investors and analysts took a "wait and watch" approach after U.S. Health Secretary Robert F. Kennedy Jr. fired all members of an expert vaccin
Investors will be waiting for news on how the makeup of a reconstituted ACIP will look like.

What Sparked Moderna Stock Crash?

07:40am, Tuesday, 10'th Jun 2025
Moderna's stock (NASDAQ: MRNA) has fallen over 80% in the last year, primarily due to issues with its vaccine sales. Last year, the company revealed reduced sales forecasts in Europe after the Europea
Vaccines stocks slipped late Monday after HHS fired all members of a CDC committee in charge of making vaccine suggestions.
Moderna, Inc. (NASDAQ:MRNA ) Jefferies Global Healthcare Conference Call June 5, 2025 10:30 AM ET Company Participants Stephen Hoge - President Conference Call Participants Michael Jonathan Yee - Jeff

Down 80%, Should You Buy the Dip on Moderna?

04:15am, Wednesday, 04'th Jun 2025
A few years ago, Moderna (MRNA 2.77%) stock represented the ticket to an investing win. The company brought its coronavirus vaccine from drawing board to commercialization in less than a year and saw
U.S. Health and Human Services Secretary Robert F. Kennedy Jr. said on Tuesday that Moderna has agreed to a true placebo-controlled trial of its new COVID-19 vaccine.
MRNA wins FDA approval for mNexspike, a fridge-stable COVID shot, but with a narrower use label than it sought.
The biotech's mRNA vaccines were lauded by the first Trump administration but now are caught up in government changes to vaccine rules.
Moderna's new COVID vaccine approval targets a broader high-risk population, but the market remains skeptical due to limited revenue prospects and ongoing losses. Management is pivoting to cost-cuttin
U.S. equities were mixed at midday after China hit back at the U.S. and accused Washington of violating a trade deal the two countries reached last month. President Donald Trump said on Friday that Ch
Moderna Inc (NASDAQ:MRNA, ETR:0QF) shares edged higher after the US Food and Drug Administration (FDA) approved its newest COVID-19 vaccine mNEXSPIKE (mRNA-1283). The vaccine was approved for use in a
Moderna said mNEXSPIKE was approved by the FDA for use in adults aged 65 and up, as well as some individuals aged 12 to 64.
The U.S. Food and Drug Administration (FDA) on Saturday approved Moderna, Inc.'s MRNA mNexspike (mRNA-1283), a new vaccine against COVID-19, for all adults 65 and older and individuals aged 12-64 yea
The U.S. Food and Drug Administration has approved Moderna's next-generation COVID-19 vaccine for all individuals aged 65 and above, the company said on Saturday, the first endorsement since the regul
Click to get the best stock tips daily for free!

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE